StreetAlpha.app
Home › Stocks › NBP

NovaBridge Biosciences (NBP)

$0.82
▲ +3.89%
LAST CLOSE · NOV 17

NovaBridge Biosciences develops drug candidates for cancer and eye disease, led by givastomig for gastric cancer. It last closed at $0.82 on Nov 17, up 3.89% on the day. NBP last reported earnings on Mon, Jun 29, 2026.

AI Auto Pilots
Is NBP in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$46.3M
Balance sheet
Cash & equivalents
$210.6M
At Dec 31
Shareholder equity
$230.9M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$365.9M−$365.9MFY2021FY2022: −$371.1M−$371.1MFY2022FY2023: −$207.7M−$207.7MFY2023FY2024: −$22.2M−$22.2MFY2024FY2025: −$46.3M−$46.3MFY2025

From NBP's SEC filings, latest 20-F/A for the period ending Dec 31, 2025 (filed Jun 16). Last 12 months adds up the four latest quarters. Per share figures are left out because the US listing can represent a different number of shares.

Last report
Jun 29
2026 · Time not announced
Reported EPS
-$0.27
vs -$0.12 est. · miss
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
—
No ratings in 90 days
Loading…

Technical Analysis

NBP · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 28% below its 20 day and 57% below its 50 day average. It is 145% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 25), oversold. The nearest support is the Pivot at $0.80, and the nearest resistance the Pivot R1 at $0.85.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 9.4%/day
Key levels
$5.1952 week high+532.9%
$2.01200 day average+145.1%
$1.56100 day average+90.2%
$1.44Swing high (Oct 6)+75.6%
$1.2950 day average+57.3%
$1.0520 day average+28.0%
$0.85Pivot R1+3.7%
$0.82Last close
$0.80Pivot−2.4%
$0.77Pivot S1−6.1%
$0.7552 week low−8.5%
Indicators
RSI (14)24.81Oversold below 30Oversold
MACD-0.15Below its signal lineBearish
Stochastic9.8Near the bottom of its rangeOversold
ADX (14)45.0Strong downtrend
Williams %R-86.5Oversold below −80, overbought above −20Oversold
CCI (20)-94.5Oversold below −100, overbought above 100Neutral
Rate of change−18.6%Change over 10 sessionsBearish
ATR (14)$0.08Typical daily range, 9.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for NBP

What happened before

See how NBP did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow NBP usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How NBP has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in NBP in the last 90 days.

Loading…

See today’s whale options flow across the market →

NBP Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ●23 buying vs 22 selling
  • ▼Shares held by funds -7.7%
  • ▼Funds holding -1
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding4849−2.0%
In funds' top 10110.0%
Held by funds–––
New / increased9 / 1413 / 13−11.5%
Reduced / sold out13 / 911 / 110.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See NBP institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NBP is in one of them and how their past NBP trades turned out.

NBP in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered NBP in an article yet. Here's the latest on the wider market.

About NovaBridge Biosciences

NovaBridge Biosciences is a biotechnology company based in Rockville, Maryland, that develops drug candidates for cancer and eye disease. Its lead program is givastomig, an antibody therapy being tested for gastric cancer and other tumors that express the CLDN18.2 protein. The company is also developing VIS-101, a candidate for wet macular degeneration and diabetic macular edema. Its treatments are aimed at patients worldwide.

Headquarters
Rockville, MD